Ambee Pharmaceuticals PLC

DSE:AMBEEPHA Stock Report

Market Cap: ৳1.7b

Ambee Pharmaceuticals Valuation

Is AMBEEPHA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AMBEEPHA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AMBEEPHA (BDT708.8) is trading above our estimate of fair value (BDT12.99)

Significantly Below Fair Value: AMBEEPHA is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AMBEEPHA?

Key metric: As AMBEEPHA is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AMBEEPHA. This is calculated by dividing AMBEEPHA's market cap by their current revenue.
What is AMBEEPHA's PS Ratio?
PS Ratio8.3x
Sales৳205.24m
Market Cap৳1.70b

Price to Sales Ratio vs Peers

How does AMBEEPHA's PS Ratio compare to its peers?

The above table shows the PS ratio for AMBEEPHA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.5x
ADVENT Advent Pharma
3xn/a৳1.6b
SILCOPHL Silco Pharmaceuticals
4.1xn/a৳1.7b
SILVAPHL Silva Pharmaceuticals
2.3xn/a৳1.4b
NAVANAPHAR Navana Pharmaceuticals
0.8xn/a৳5.4b
AMBEEPHA Ambee Pharmaceuticals
8.3xn/a৳1.7b

Price-To-Sales vs Peers: AMBEEPHA is expensive based on its Price-To-Sales Ratio (8.3x) compared to the peer average (2.5x).

Price to Sales Ratio vs Industry

How does AMBEEPHA's PS Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

49 CompaniesPrice / SalesEstimated GrowthMarket Cap
AMBEEPHA 8.3xIndustry Avg. 2.7xNo. of Companies82PS0246810+
49 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: AMBEEPHA is expensive based on its Price-To-Sales Ratio (8.3x) compared to the Asian Pharmaceuticals industry average (2.7x).

Price to Sales Ratio vs Fair Ratio

What is AMBEEPHA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AMBEEPHA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate AMBEEPHA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies